PGR, progesterone receptor, 5241

N. diseases: 392; N. variants: 33
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 AlteredExpression disease BEFREE Moreover, all grade I meningiomas with a low Ki-67 expression and a positive PR expression did not have the same metabolomic profile. 31679342 2020
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 AlteredExpression disease BEFREE Neurofibromatosis type 2 gene mutation and progesterone receptor messenger RNA expression in the pathogenesis of sporadic orbitocranial meningioma. 31024808 2019
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 AlteredExpression disease BEFREE Development of predictive markers of recurrences may also identify high-risk patients, including proliferative markers and expression of the progesterone receptor in meningiomas, and lead to less aggressive surgery. 30779850 2019
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 AlteredExpression disease BEFREE Meningiomas are more common in females and 70-80% express the progesterone receptor, raising the possibility that high-dose exogenous estrogen/progesterone exposure, such as occurs during fertility treatments, may increase the risk of developing a meningioma. 30868355 2019
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 AlteredExpression disease BEFREE Progesterone receptor (PR) expression and mifepristone treatment was highly discussed for meningiomas. 29453736 2019
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 Biomarker disease BEFREE We examined immunohistochemically the expression of MUC4, progesterone receptor (PgR) and somatostatin receptor 2A (SSTR2A) in 140 meningiomas of various histological subtypes and 123 other mesenchymal tumours, including intracranial or sinonasal tumours and peripheral nerve sheath tumours. 30112770 2019
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 Biomarker disease BEFREE The medical records from 366 patients treated for meningiomas from 2003 to 2016 were retrospectively analyzed for age, gender, anatomical localization, recurrence-free survival, overall survival, histopathological diagnosis, and immunohistochemistry findings for 6 markers: epithelial membrane antigen (EMA), progesterone receptor (PR), CD34, S100, p53, and Ki-67 labeling index. 30503291 2019
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 AlteredExpression disease BEFREE The rate of meningiomas with PR expression ≤ 50% was significantly lower in medial skull base (25%) than in non-skull base (48%) (p = 0.009). 31637512 2019
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 Biomarker disease BEFREE The expression rate of SSTR2a was higher than that of conventional markers of meningioma, including EMA (86/138), PR (32/68) and S100 (1/125). 31208995 2019
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 Biomarker disease BEFREE Histological diagnosis confirmed a strong progesterone receptor-positive and slight estrogen positive meningioma. 29105524 2018
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 GeneticVariation disease BEFREE Significant association between lower expression of PR (OR 11.7; 95% CI 4.17-32.9; <i>P</i> < 0.001 comparing the lowest quartile vs. 3 highest quartile of PR) and <i>NF2</i> (OR 4.23; 95% CI 1.85-9.67; <i>P</i> = 0.001 comparing the 2 lowest quartiles vs. 2 highest quartiles) with increased risk of meningioma were also reported. 30687635 2018
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 Biomarker disease BEFREE As the Ki-67 index and WHO grade were not different between these locations, the high rate of positive PGR may be responsible for the benign biology of skull base meningiomas. 30031954 2018
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 AlteredExpression disease BEFREE Evaluation of 1p and 14q status, MIB-1 labeling index and progesterone receptor immunoexpression in meningiomas: Adjuncts to histopathological grading and predictors of aggressive behavior. 25237942 2014
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 AlteredExpression disease BEFREE The majority of MM and FM samples were strongly positive for LHRH-R expression and PR expression. 24100643 2013
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 Biomarker disease CTD_human Regression of multiple intracranial meningiomas after cessation of long-term progesterone agonist therapy. 19731987 2010
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 AlteredExpression disease BEFREE In the clinical samples of meningioma, the levels of cathepsins B and L, stefin B, and cystatin C were highest in the tumors of higher histological grades, whereas stefin A and progesterone receptor were the only markers that were significantly increased and decreased, respectively, in WHO Grade III lesions. 19747051 2010
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 Biomarker disease CTD_human In the clinical samples of meningioma, the levels of cathepsins B and L, stefin B, and cystatin C were highest in the tumors of higher histological grades, whereas stefin A and progesterone receptor were the only markers that were significantly increased and decreased, respectively, in WHO Grade III lesions. 19747051 2010
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 AlteredExpression disease LHGDN Eighty-two specimens of human meningiomas were obtained for immunohistochemical analysis with anti-GnRH, anti-GnRH-R, anti-PR, anti-ER, and anti-Ki-67 (MIB-1) antibodies, and for RT-PCR analysis of the mRNA expressions of GnRH and GnRH-R. Correlations of GnRH and GnRH-R with PR, ER, Ki-67, and clinical features such as age, sex, tumor grade, and tumor histology were assessed. 18980792 2009
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 Biomarker disease BEFREE This study aims to determine the status of GnRH and GnRH-R and to elucidate the correlations of GnRH and GnRH-R with PR, ER, and clinical features in meningiomas. 18980792 2009
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 Biomarker disease BEFREE In order to better define the pathogenetic roles of these proteins, we studied the merlin, DAL-1, and PR immunoprofiles in 175 fully characterized meningiomas, including nonrecurring versus recurring benign, proliferative versus brain invasive atypical and anaplastic subtypes. 11079777 2000
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 Biomarker disease BEFREE It is therefore concluded that ERDelta5 mRNA does not play the dominant role in PR synthesis in meningioma tissue. 10704905 1999
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 Biomarker disease BEFREE We have investigated the presence of both ER and PgR in a series of 20 human meningiomas, spanning the main histological groups, using reverse transcription linked PCR (RT-PCR). 9311583 1997
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 AlteredExpression disease BEFREE An increase in transcription was observed with the addition of promegestone (R5020), a progesterone agonist, only in meningioma cell cultures that were expressing the progesterone receptor. 8587697 1995
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 Biomarker disease CTD_human Sphenoid wing meningioma progression after placement of a subcutaneous progesterone agonist contraceptive implant. 8008172 1994
CUI: C0025286
Disease: Meningioma
Meningioma
0.400 Biomarker disease BEFREE EGF-R was present in almost half and progesterone receptor in most of the meningiomas. 7754837 1994